



TRACON Pharmaceuticals Announces Appointment of Brian Daniels, M.D., to Scientific Advisory Board

December 4, 2017

SAN DIEGO, Dec. 04, 2017 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration (AMD) and fibrotic diseases, today announced the appointment of Brian Daniels, M.D., to the Company's Scientific Advisory Board (SAB).

"Brian brings extensive experience in the immune oncology area to our SAB, and we are thrilled to add his expertise to our team," said Charles P. Theuer, M.D., Ph.D., President and CEO of TRACON. "He was instrumental in the clinical development and commercialization of several immune oncology assets at BMS, and his experience should prove particularly valuable as we begin a trial of our lead antibody, TRC105, in combination with Opdivo in lung cancer."

"I look forward to working with the team at TRACON and am excited about this opportunity to contribute to the science and clinical strategy," said Dr. Daniels.

Dr. Daniels was Senior Vice President at Bristol-Myers Squibb until 2014, where he chaired the development investment committee and directed the development of Sprycel® (dasatinib), Ixempra® (ixabepilone), Yervoy® (ipilimumab), Empliciti® (elotuzumab), and Opdivo® (nivolumab). He is currently a venture partner at 5AM Ventures, and also previously held senior level development-related positions at Merck and Genentech. In addition, Dr. Daniels previously served in multiple academic roles in the Department of Medicine at the University of California, San Francisco.

Dr. Daniels earned his B.S. and M.S. from the Massachusetts Institute of Technology and an M.D. from Washington University in St. Louis. He completed his residency in internal medicine at New York Hospital, and a fellowship in rheumatology at the University of California, San Francisco.

About TRACON

TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company's clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma; and TRC253, a small molecule that is being developed for the treatment of prostate cancer. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.

Company Contact:

Casey Logan
Chief Business Officer
(858) 550-0780 ext. 236
clogan@traconpharma.com

Investor Contact:

Andrew McDonald
LifeSci Advisors LLC
646-597-6987
Andrew@lifesciadvisors.com

 [Primary Logo](#)

Source: TRACON Pharmaceuticals, Inc.